Downloads: 775

Files in This Item:
File Description SizeFormat 
s12929-017-0329-9.pdf842.2 kBAdobe PDFView/Open
Title: Cancer immunotherapies targeting the PD-1 signaling pathway
Authors: Iwai, Yoshiko
Hamanishi, Junzo  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7750-0623 (unconfirmed)
Chamoto, Kenji  kyouindb  KAKEN_id
Honjo, Tasuku
Author's alias: 濱西, 潤三
茶本, 健司
本庶, 佑
Keywords: PD-1
PD-L1
Cancer immunotherapy
Immune checkpoint
Issue Date: 4-Apr-2017
Publisher: Springer Nature
Journal title: Journal of Biomedical Science
Volume: 24
Thesis number: 26
Abstract: Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.
Rights: © The Author(s). 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
URI: http://hdl.handle.net/2433/225265
DOI(Published Version): 10.1186/s12929-017-0329-9
PubMed ID: 28376884
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.